

30 November 2020

Tender results

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018 and the 2019/20 Invitation to Tender, dated 1 November 2019.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 11th of December or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 11th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information.

[More information about this process and NOPC forms can be found on our website.](#)

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 11 December 2020 (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Loratadine	Oral liq 1 mg per ml; 100 ml bottle pack	\$2.95 (120 ml bottle pack)	\$1.43	Lora Syrup (Boucher and Muir)	1 April 2021	1 September 2021	Lorfast (Multichem)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Loratadine	Oral liq 1 mg per ml; 100 ml bottle pack	\$2.95 (120 ml bottle pack)	\$1.43	Lora Syrup (Boucher and Muir)	1%	1 April 2021	1 September 2021	Lorfast (Multichem)

2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Teriflunomide	Tab 14 mg; 28 tablet blister pack	\$1,582.62	\$659.90	Aubagio (Sanofi)	1 March 2021	1 June 2021

4. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Sole supply brand (Supplier)	Date of listing	Sole Subsidised Supply date	Brand (Supplier) affected by delisting
Febuxostat ¹	Tab 80 mg; 28 tablet blister pack	\$39.50	\$20.00	Febuxostat Multichem (Multichem)	1 August 2021	1 January 2022	Adenuric (A.Menarini)
Febuxostat ¹	Tab 120 mg; 28 tablet blister pack	\$39.95	\$20.00	Febuxostat Multichem (Multichem)	1 August 2021	1 January 2022	Adenuric (A.Menarini)
1. Brand switch fee of \$4.50 is payable for this product from 1 January 2022 until 31 March 2022							

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Teriflunomide	Tab 14 mg; 28 tablet blister pack	\$1,582.62	\$659.90	Aubagio (Sanofi)	1%	1 March 2021	1 June 2021

6. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Hospital supply brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date	Brand (Supplier) affected by delisting
Febuxostat	Tab 80 mg; 28 tablet blister pack	\$39.50	\$20.00	Febuxostat Multichem (Multichem)	1%	1 August 2021	1 January 2022	Adenuric (A.Menarini)
Febuxostat	Tab 120 mg; 28 tablet blister pack	\$39.50	\$20.00	Febuxostat Multichem (Multichem)	1%	1 August 2021	1 January 2022	Adenuric (A.Menarini)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

- the 2019/20 Invitation to Tender, dated 1 November 2019

2019/20 Invitation to Tender

Chemical name	Line item
Teriflunomide (Widened access)	Tab 14 mg

For products included in the 2018/19 and 2019/20 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.